TNDM
HealthcareTandem Diabetes Care, Inc. · Medical - Devices · $1B
What is Tandem Diabetes Care, Inc.?
Tandem Diabetes Care is a San Diego-based medical device company focused on insulin delivery solutions for people with insulin-dependent diabetes, serving customers in the United States and internationally.
Tandem designs and commercializes insulin pump systems and supporting software tools. Revenue comes from pump hardware sales, disposable cartridges, infusion sets, and software-enabled platform upgrades. The company also offers data management applications that connect patients, caregivers, and clinicians, and has commercialization agreements with Dexcom and Abbott Laboratories.
Incorporated in 2006 and headquartered in San Diego, California, the company adopted its current name in January 2008.
- t:slim X2 insulin pump platform
- Control-IQ and Basal-IQ automated insulin delivery technology
- t:connect web-based diabetes data management application
- Sugarmate mobile app for insulin-using patients
Is TNDM a Good Stock to Buy?
UQS Score rates TNDM as Poor overall, reflecting meaningful challenges across several key quality dimensions.
The Growth and Risk pillars both land at Neutral, suggesting the business is not in freefall and carries a manageable near-term risk profile relative to its stage.
Quality and Moat are both rated Weak, and Valuation is Elevated — a combination that signals the stock may be priced beyond what current fundamentals support.
Sign up to see the full pillar breakdown and underlying financial metrics behind TNDM's UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TNDM pay dividends?
No — Tandem Diabetes Care, Inc. does not currently pay a dividend.
Tandem Diabetes Care does not currently pay a dividend. As a growth-stage medical device company, capital is directed toward product development, regulatory efforts, and commercial expansion rather than shareholder distributions.
When does TNDM report earnings?
Tandem Diabetes Care reports earnings on a quarterly cadence, consistent with US-listed public companies.
Quarterly results tend to reflect trends in pump shipments, international expansion progress, and operating cost management. Investors typically watch for updates on new product adoption and partnership developments with Dexcom and Abbott.
For the most recent quarter's results, visit Tandem Diabetes Care's investor relations page directly.
TNDM Price History
-76.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Tandem Diabetes Care, Inc.?
Based on Tandem Diabetes Care, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Tandem Diabetes Care do?
Tandem Diabetes Care designs and sells insulin pump systems and related software for people with insulin-dependent diabetes. Its flagship t:slim X2 platform integrates with continuous glucose monitors and uses automated insulin delivery algorithms to help patients manage blood sugar.
Does TNDM pay dividends?
No, TNDM does not pay a dividend. The company reinvests available resources into product development and commercial growth rather than returning cash to shareholders through distributions.
When does TNDM report earnings?
Tandem Diabetes Care follows a standard quarterly reporting schedule. For confirmed dates and the latest financial releases, check the investor relations section of the company's official website.
Is TNDM a good stock to buy?
UQS Score rates TNDM as Poor, driven by Weak Quality and Moat scores alongside an Elevated Valuation. Investors should weigh these structural concerns carefully. The full pillar breakdown is available to Pro members on UQS Score.
Is TNDM overvalued?
TNDM's Valuation pillar is rated Elevated, suggesting the current market price may not be well supported by the company's underlying financial quality. This is particularly notable given the Weak Quality and Moat ratings.
What is TNDM's market cap bracket?
TNDM is classified as a small-cap stock, meaning it carries a relatively modest market capitalization compared to large or mega-cap peers in the broader healthcare and medical device sector.
Is TNDM a long-term quality investment?
As a long-term quality indicator, TNDM's Poor UQS Score — anchored by Weak Quality and Moat pillars — raises questions about durability of competitive position and earnings power. Monitoring improvement in these pillars over time would be a key signal for long-term investors.
What sector does TNDM belong to?
Tandem Diabetes Care operates in the Healthcare sector, specifically within medical devices. It competes in the insulin delivery and diabetes management technology space, a segment shaped by regulatory requirements and clinical adoption cycles.
Unlock Full TNDM Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown for TNDM
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare TNDM against peers in the medical device space
- ✓Track score changes as new earnings data becomes available
Pro Analysis
TNDM — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 33.4 | 16.7 | 32.0 | 46.4 | 58.8 | 21.2 | -0.1 |
| May 21, 2026 | 33.5 | 16.7 | 32.0 | 46.4 | 58.8 | 21.8 | -0.5 |
| May 19, 2026 | 34.0 | 16.7 | 32.0 | 46.4 | 58.8 | 24.9 | -0.4 |
| May 16, 2026 | 34.4 | 16.7 | 32.0 | 46.4 | 58.8 | 27.5 | +8.8 |
| May 10, 2026 | 25.6 | 0.0 | 32.0 | 46.5 | 36.9 | 18.3 | -4.2 |
| May 5, 2026 | 29.8 | 16.7 | 32.0 | 46.6 | 54.6 | 0.8 | 0.0 |
| Apr 26, 2026 | 29.8 | 16.7 | 32.0 | 46.6 | 54.6 | 1.2 | 0.0 |
| Apr 22, 2026 | 29.8 | 16.7 | 32.0 | 46.4 | 54.6 | 1.2 | +0.1 |
| Apr 16, 2026 | 29.7 | 16.7 | 32.0 | 46.0 | 54.6 | 0.7 | 0.0 |
| Apr 11, 2026 | 29.7 | 16.7 | 32.0 | 46.2 | 54.6 | 0.9 | 0.0 |
TNDM — Pillar Breakdown
Quality
— 16.7/100 (25%)Tandem Diabetes Care, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 46.4/100 (20%)Tandem Diabetes Care, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 58.8/100 (15%)Tandem Diabetes Care, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 21.9/100 (15%)Tandem Diabetes Care, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 32/100 (25%)Tandem Diabetes Care, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TNDM.
Score Composition
Financial Data
More Stock Analysis
How is the TNDM UQS Score Calculated?
The UQS (Unified Quality Score) for Tandem Diabetes Care, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Tandem Diabetes Care, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Tandem Diabetes Care, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.